Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States
Jessica Leung, Scott D. Grosse, Bryan Yockey, Tatiana M. Lanzieri
Abstract
Among 342 US infants with congenital cytomegalovirus treated with antivirals, 114 (33%) received ganciclovir (with or without valganciclovir) and 228 (67%) received valganciclovir only, for a median of 8 and 171 days, starting at a median of 15 and 45 days of life, respectively, with neutropenia diagnosed in 25% and 17%.
Topics & Concepts
ValganciclovirGanciclovirMedicineCytomegalovirusNeutropeniaCytomegalovirus infectionsPediatricsInternal medicineHuman cytomegalovirusVirologyChemotherapyVirusHerpesviridaeViral diseaseCytomegalovirus and herpesvirus researchNeonatal Health and BiochemistryHerpesvirus Infections and Treatments